Zhe Wang1, Jingshuai Wang2, Liu Fu1, Shuang Dong1, Yanli Ge1, Junjie Zhang1, Binbin Huang1, Qizhi Wang3, Zhirong Wang1. 1. Department of Gastroenterology, Tongji Hospital, Tongji University School of Medicine Shanghai 200065, China. 2. Department of Obstetrics and Gynecology, Tongji Hospital, Tongji University School of Medicine Shanghai 200065, China. 3. Department of Gastroenterology, The First Affiliated Hospital, Bengbu Medical College Anhui 233400, China.
Abstract
OBJECTIVE: Infliximab (IFX) monotherapy and IFX combined with immunosuppressors have been used in the treatment of Crohn's disease. However, the differences between combination therapy and IFX alone remain controversial. The aim of this meta-analysis was to evaluate the effectiveness and risk associated with combination therapy and IFX monotherapy. METHODS: Systematic searches were performed for randomized controlled trials with PubMed, Web of Science, OVID, and the Cochrane Library. The analyzed contents included induction of remission, short-term maintenance of remission, long-term maintenance of remission, and risks. The final results were estimated using statistical data of odds ratio (OR), relevant 95% confidence interval (CI), and P value. RESULTS: 6 out of 1041 citations met the selection criteria. There was no statistical difference in the effectiveness of induction and long-term maintenance of remission between two groups (P=0.07, 0.12). However, for short-term maintenance of remission, there was mild statistical difference between two groups (P=0.02, OR=1.66). For risks, apart from the difference in the aspect of reaction to infusion (OR=0.43, 95% CI=0.29-0.65, P<0.0001), there was no statistical difference. CONCLUSIONS: There was no significant difference in effectiveness and risks between the therapy groups. However, these outcomes should be interpreted with caution. Specific categories of combination therapy and periodic medication should be paid more attention in future studies.
OBJECTIVE:Infliximab (IFX) monotherapy and IFX combined with immunosuppressors have been used in the treatment of Crohn's disease. However, the differences between combination therapy and IFX alone remain controversial. The aim of this meta-analysis was to evaluate the effectiveness and risk associated with combination therapy and IFX monotherapy. METHODS: Systematic searches were performed for randomized controlled trials with PubMed, Web of Science, OVID, and the Cochrane Library. The analyzed contents included induction of remission, short-term maintenance of remission, long-term maintenance of remission, and risks. The final results were estimated using statistical data of odds ratio (OR), relevant 95% confidence interval (CI), and P value. RESULTS: 6 out of 1041 citations met the selection criteria. There was no statistical difference in the effectiveness of induction and long-term maintenance of remission between two groups (P=0.07, 0.12). However, for short-term maintenance of remission, there was mild statistical difference between two groups (P=0.02, OR=1.66). For risks, apart from the difference in the aspect of reaction to infusion (OR=0.43, 95% CI=0.29-0.65, P<0.0001), there was no statistical difference. CONCLUSIONS: There was no significant difference in effectiveness and risks between the therapy groups. However, these outcomes should be interpreted with caution. Specific categories of combination therapy and periodic medication should be paid more attention in future studies.
Authors: Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts Journal: Gut Date: 2007-01-17 Impact factor: 23.059
Authors: S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: C Lahiff; P Safaie; A Awais; M Akbari; L Gashin; S Sheth; A Lembo; D Leffler; A C Moss; A S Cheifetz Journal: Aliment Pharmacol Ther Date: 2013-02-21 Impact factor: 8.171
Authors: W Miehsler; G Novacek; H Wenzl; H Vogelsang; P Knoflach; A Kaser; C Dejaco; W Petritsch; M Kapitan; H Maier; W Graninger; H Tilg; W Reinisch Journal: J Crohns Colitis Date: 2010-03-17 Impact factor: 9.071
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: G R Lichtenstein; R H Diamond; C L Wagner; A A Fasanmade; A D Olson; C W Marano; J Johanns; Y Lang; W J Sandborn Journal: Aliment Pharmacol Ther Date: 2009-04-21 Impact factor: 8.171